SCHEMBL286240

SCHEMBL286240

Cc1onc(-c2ccc(F)cc2)c1C=Cc1cc(C(=O)N2CC3(COC3)C2)[nH]n1

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GABRA5 P31644 7/20 0.40
HDAC2 Q92769 2/20 0.39
HDAC3 O15379 1/20 0.39
HDAC1 Q13547 1/20 0.39
GABRA1 P14867 2/20 0.38
KDM4E B2RXH2 1/20 0.37
TACR3 P29371 1/20 0.34
PARP1 P09874 1/20 0.34
PTGS2 P35354 2/20 0.33
GAA P10253 1/20 0.33
TSHR P16473 1/20 0.33
LRRK2 Q5S007 1/20 0.33
MAPK1 P28482 1/20 0.33
GABRG2 P18507 1/20 0.33
GABRB3 P28472 1/20 0.33
GABRA3 P34903 1/20 0.33
GABRA2 P47869 1/20 0.33
GRIA1 P42261 1/20 0.33
KDM5B Q9UGL1 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL286239 1.00 GABRA5 (0.40) GABRA5HDAC2HDAC3HDAC1GABRA1
SCHEMBL286296 0.86 GABRA5 (0.47) GABRA5KDM4ETACR3TSHRGABRG2
SCHEMBL286295 0.86 GABRA5 (0.47) GABRA5KDM4ETACR3TSHRGABRG2
SCHEMBL285751 0.83 GABRA5 (0.49) GABRA5GABRA1KDM4ETACR3MAPK1
SCHEMBL2628083 0.83 GABRA5 (0.49) GABRA5GABRA1KDM4ETACR3MAPK1
SCHEMBL286307 0.82 GABRA5 (0.40) GABRA5HDAC2HDAC3HDAC1GABRA1
SCHEMBL286308 0.82 GABRA5 (0.40) GABRA5HDAC2HDAC3HDAC1GABRA1
SCHEMBL286110 0.81 ALPL (0.48) GABRA5KDM4EPTGS2GAATSHR
SCHEMBL285881 0.81 KDM4E (0.43) GABRA5KDM4EPTGS2GAATSHR
SCHEMBL285882 0.81 KDM4E (0.43) GABRA5KDM4EPTGS2GAATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8163728-B2 Pyrazoles HOFFMANN-LA ROCHE INC. (US) 2012-04-24 US claimed
US-20100286115-A1 PYRAZOLES ROCHE PALO ALTO LLC 2010-11-11 US claimed
US-8163728-B2 Pyrazoles HOFFMANN-LA ROCHE INC. (US) 2012-04-24 US disclosed
EP-2427455-A1 ISOXAZOLE-PYRAZOLE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2012-03-14 EP disclosed
WO-2010127975-A1 ISOXAZOLE-PYRAZOLE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2010-11-11 WO disclosed
US-20100286115-A1 PYRAZOLES ROCHE PALO ALTO LLC 2010-11-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100286115-A1 PYRAZOLES GABRA5, GABRA1, GABRA3 GABRA5 1/4885HDAC2 1528/4885HDAC3 2058/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.